At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IONS Ionis Pharmaceuticals
Trading 12-16 15:43:34 EST
78.48
-1.28
-1.61%
High79.56Low77.16Vol1.26M
Open79.41D1 Closing79.76Amplitude3.00%
Mkt Cap12.71BTradable Cap12.63BTotal Shares161.97M
T/O98.19MT/O Rate0.78%Tradable Shares161.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Dow Jones  ·  12-16 04:55
Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $100 From $85
THOMSON REUTERS  ·  12-15 19:59
Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $100 From $85
Ionis Pharmaceuticals (IONS): Revisiting Valuation After a Strong 1-Year Share Price Surge
Simply Wall St.  ·  12-10
Ionis Pharmaceuticals (IONS): Revisiting Valuation After a Strong 1-Year Share Price Surge
Ionis Pharmaceuticals Is Maintained at Buy by B of A Securities
Dow Jones  ·  12-10
Ionis Pharmaceuticals Is Maintained at Buy by B of A Securities
Ionis Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $97 From $86
THOMSON REUTERS  ·  12-09
Ionis Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $97 From $86
Ionis Pharmaceuticals Director Joseph H. Wender Reports Sale of Common Shares
Reuters  ·  12-04
Ionis Pharmaceuticals Director Joseph H. Wender Reports Sale of Common Shares
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
Benzinga_recent_news  ·  12-03
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease
Reuters  ·  12-02
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease
Ionis Receives U.S. FDA Breakthrough Therapy Designation for Zilganersen for Alexander Disease (Axd)
THOMSON REUTERS  ·  12-02
Ionis Receives U.S. FDA Breakthrough Therapy Designation for Zilganersen for Alexander Disease (Axd)
Ionis Pharmaceuticals Inc - on Track to Submit Nda for Zilganersen in Q1 2026
THOMSON REUTERS  ·  12-02
Ionis Pharmaceuticals Inc - on Track to Submit Nda for Zilganersen in Q1 2026
Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen
Simply Wall St.  ·  12-02
Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen
Ionis Pharmaceuticals Shares Reverse Premarket Course, Last Down 2.4%
THOMSON REUTERS  ·  12-01
Ionis Pharmaceuticals Shares Reverse Premarket Course, Last Down 2.4%
Ionis Pharmaceuticals Shares up 3.5% Premarket After Co Receives FDA Breakthrough Therapy Designation for Olezarsen for Shtg
THOMSON REUTERS  ·  12-01
Ionis Pharmaceuticals Shares up 3.5% Premarket After Co Receives FDA Breakthrough Therapy Designation for Olezarsen for Shtg
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Olezarsen for Severe Hypertriglyceridemia
Reuters  ·  12-01
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Olezarsen for Severe Hypertriglyceridemia
Ionis Pharmaceuticals Inc: on Track to Submit Supplemental New Drug Application by End of Year
THOMSON REUTERS  ·  12-01
Ionis Pharmaceuticals Inc: on Track to Submit Supplemental New Drug Application by End of Year
Ionis Receives U.S. FDA Breakthrough Therapy Designation for Olezarsen for Severe Hypertriglyceridemia (Shtg)
THOMSON REUTERS  ·  12-01
Ionis Receives U.S. FDA Breakthrough Therapy Designation for Olezarsen for Severe Hypertriglyceridemia (Shtg)
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
GlobeNewswire  ·  12-01
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
Why Ionis Pharmaceuticals (IONS) Is Up 8.7% After Donidalorsen EMA Milestone and $700 Million Offering News
Simply Wall St.  ·  11-30
Why Ionis Pharmaceuticals (IONS) Is Up 8.7% After Donidalorsen EMA Milestone and $700 Million Offering News
Ionis Pharmaceuticals EVP Chief Human Resources Officer Shannon L. Devers Reports Sale of Common Shares
Reuters  ·  11-29
Ionis Pharmaceuticals EVP Chief Human Resources Officer Shannon L. Devers Reports Sale of Common Shares
Ionis Pharmaceuticals Director Joseph Klein III Reports Disposal of Common Shares
Reuters  ·  11-29
Ionis Pharmaceuticals Director Joseph Klein III Reports Disposal of Common Shares

Introduction

Company Name.
Ionis Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Issue price:
--